-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Primary immune thrombocytopenia (ITP) is a rare acquired immune diseases, wherein the platelet count <10 × 100 .
Primary immune thrombocytopenia (ITP) is a rare acquired immune diseases, wherein the platelet count <10 × 100 .
However, the effectiveness and safety of thrombopoietin receptor agonists (TRA) in elderly patients with ITP are still unclear
TRA reactivity and dressing change, thrombosis /bleeding risk, and sustained remission (SROT) after stopping treatment were evaluated in 384 ITP patients 60 years and older.
Multivariate analysis and risk factors of TRA treatment failure
Multivariate analysis and risk factors of TRA treatment failureAfter 3 months of continuous treatment, 82.
After 3 months of continuous treatment, 82.
prevention
Treatment-free remission period after discontinuation of TRA in patients in different remission states
Treatment-free remission period after discontinuation of TRA in patients in different remission statesSixty-two (16.
62 (16.
TRA is an effective therapy for elderly patients with ITP, and there is no risk of fatal bleeding.
Original source:
Francesca Palandri, et al.
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia
in this message
